 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12345678910111213...208209» |
- | ribupatide injection (HRS9531 injection) / Kailera Therapeutics
Enrollment status: Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes (clinicaltrials.gov) - May 29, 2026
P2, N=250, Enrolling by invitation, Sponsor: Kailera
Recruiting --> Enrolling by invitation
- | Avastin (bevacizumab) / Roche, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Trial completion date, Trial suspension, Trial primary completion date: OBU-HCC-II-001: Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma (clinicaltrials.gov) - May 29, 2026
P2, N=40, Suspended, Sponsor: Tianjin Medical University Cancer Institute and Hospital
Recruiting --> Enrolling by invitation Trial completion date: Aug 2027 --> Aug 2028 | Recruiting --> Suspended | Trial primary completion date: May 2025 --> May 2027
- | Trial completion date, Trial primary completion date: FASCINATE-N: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (clinicaltrials.gov) - May 29, 2026
P2, N=716, Recruiting, Sponsor: Fudan University
Trial completion date: Aug 2027 --> Aug 2028 | Recruiting --> Suspended | Trial primary completion date: May 2025 --> May 2027 Trial completion date: Sep 2028 --> Sep 2029 | Trial primary completion date: Dec 2026 --> Dec 2027
- |||||||||| Ac225-zadavotide guraxetan (AZD2265) / AstraZeneca
New P3 trial: AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) (clinicaltrials.gov) - May 28, 2026
P3, N=670, Recruiting, Sponsor: AstraZeneca
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
New P2 trial: Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer (clinicaltrials.gov) - May 28, 2026
P2, N=57, Recruiting, Sponsor: Sun Yat-sen University
- AiRuiKa (camrelizumab) / Elevar Therapeutics
Phase 2 Trial of First-Line Camrelizumab plus Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Oral Squamous Cell Carcinoma: Outcomes and Toxicity Profile (Screen: 7) - May 28, 2026 - Abstract #ASTRO2026ASTRO_923;
- AiTan (rivoceranib) / Elevar Therapeutics, Focus V (anlotinib) / Advenchen
Preoperative Radiotherapy with Anlotinib or Apatinib Improves Disease-Free Survival for Locally Advanced Soft Tissue Sarcoma: Results of Prospective Phase II Clinical Trials () - May 28, 2026 - Abstract #ASTRO2026ASTRO_721;
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Adebrelimab as Maintenance Therapy Following Hyperfractionated Simultaneous Integrated Boost Radiotherapy Plus Chemotherapy in Limited-Stage Small-Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Phase II Trial () - May 28, 2026 - Abstract #ASTRO2026ASTRO_661;
- AiRuiKa (camrelizumab) / Elevar Therapeutics
Efficacy of Chemoradiotherapy Combined with Camrelizumab in Patients with Oligometastatic Esophageal Squamous Cell Carcinoma Who Previously Received Definitive Treatment: Preliminary Results of a Phase II Trail () - May 28, 2026 - Abstract #ASTRO2026ASTRO_451;
- AiRuiKa (camrelizumab) / Elevar Therapeutics
Consolidative Camrelizumab Following Definitive Concurrent Chemoradiotherapy In Locally Advanced Esophageal Squamous Cell Carcinoma: A Single-Arm Phase 2 Trial () - May 28, 2026 - Abstract #ASTRO2026ASTRO_378;
- ||||| sonesitatug vedotin (AZD0901) / AstraZeneca
Enrollment closed, Monotherapy: CLARITY-Gastric 01: AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (clinicaltrials.gov) - May 28, 2026
P3, N=592, Active, not recruiting, Sponsor: AstraZeneca
Trial completion date: Sep 2028 --> Sep 2029 | Trial primary completion date: Dec 2026 --> Dec 2027 Recruiting --> Active, not recruiting
- || HRS-8080 / Jiangsu Hengrui Pharma
Trial completion: HRS-8080-102: A Clinical Study to Evaluate the Relative Bioavailability and Food Effect of HRS-8080 in Healthy Subjects (clinicaltrials.gov) - May 27, 2026
P1, N=24, Completed, Sponsor: Shandong Suncadia Medicine Co., Ltd.
Recruiting --> Active, not recruiting Not yet recruiting --> Completed
- | retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
New P2 trial: A Clinical Study of SHR-1701 Combined With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Siewert Type II Adenocarcinoma of the Esophagogastric Junction (clinicaltrials.gov) - May 26, 2026
P2, N=38, Not yet recruiting, Sponsor: Hebei Medical University Fourth Hospital
- decitabine / Generic mfg.
A Retrospective Analysis of Low-Dose Decitabine combined with thrombopoietin receptor agonists for Refractory Severe Cancer therapy-induced thrombocytopenia: Efficacy, Safety, and Prognostic Factors (Exhibition Hall) - May 25, 2026 - Abstract #ISTH2026ISTH_2605;
- Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Efficacy and safety of hetrombopag in children with primary immune thrombocytopenia: a longitudinal prospective cohort study (Exhibition Hall- Poster Area) - May 25, 2026 - Abstract #ISTH2026ISTH_740;
P
Conclusions These findings suggest that hetrombopag has efficacy, durability and a favorable safety profile in pediatric patients, even in those with prior eltrombopag unresponsive or relapse. DOI*10.1016/j.rpth.2026.104435
- Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Treatment-free remission after Hetrombopag discontinuation in patients with Chronic immune thrombocytopenia in China: an observational retrospective analysis in real-world clinical practice (Exhibition Hall) - May 25, 2026 - Abstract #ISTH2026ISTH_739;
- Network meta-analysis comparing the efficacy of subsequent treatment regimens in primary immune thrombocytopenia patients (Exhibition Hall- Poster Area) - May 25, 2026 - Abstract #ISTH2026ISTH_705;
Conclusions These results furnish high-quality evidence to support evidence-based, individualized selection of subsequent therapy for adults with relapsed/refractory primary immune thrombocytopenia. Table or Figure Upload (1) Figure 1.Network meta-analysis comparing the efficacy of subsequent treatment regimens Page 2 DOI*10.1016/j.rpth.2026.104395
- | retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
Clinical, Retrospective data, Review, Journal: Optimal First-line Immune-related Therapy Selection for Advanced Gastric Cancer: A Systematic Review and Network Meta-analysis. (Pubmed Central) - May 24, 2026
These findings support personalized therapy selection but await confirmation by head?to?head trials. Future studies should address CPS?<?1 and explore optimized combinations to enhance outcomes.
- | AiRuiKa (camrelizumab) / Elevar Therapeutics
New P2 trial: Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - May 23, 2026
P2, N=57, Recruiting, Sponsor: Sun Yat-sen University
- || HR17031 / Jiangsu Hengrui Pharma
Trial completion, Enrollment change: A Trial of HR17031 Injection With Renal Insufficiency (clinicaltrials.gov) - May 22, 2026
P1, N=24, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Future studies should address CPS?<?1 and explore optimized combinations to enhance outcomes. Not yet recruiting --> Completed | N=48 --> 24
- ||||||| HRS-7535 / Kailera Therapeutics
Trial completion: A Study of HRS-7535 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Diet and Exercise (clinicaltrials.gov) - May 22, 2026
P3, N=284, Completed, Sponsor: Shandong Suncadia Medicine Co., Ltd.
Not yet recruiting --> Completed | N=48 --> 24 Active, not recruiting --> Completed
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Clinical, Retrospective data, Journal, Real-world evidence: Pertuzumab Vs. Pyrotinib in Combination With Trastuzumab and Taxanes for First-Line Treatment of HER2+ MBC: A Multicenter Real-World Study. (Pubmed Central) - May 21, 2026
THPy may provide PFS benefit over THP in HER2+ MBC, with suggestive advantages in patients with de novo stage IV disease and liver metastasis. A higher frequency of diarrhea and other gastrointestinal toxicities was observed in the THPy regimen.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
New P4 trial, Real-world evidence: Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer (clinicaltrials.gov) - May 20, 2026
P4, N=500, Not yet recruiting, Sponsor: Peking University People's Hospital
- | AiRuiKa (camrelizumab) / Elevar Therapeutics
Trial initiation date: DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI (clinicaltrials.gov) - May 19, 2026
P2, N=120, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
A higher frequency of diarrhea and other gastrointestinal toxicities was observed in the THPy regimen. Initiation date: Aug 2025 --> Nov 2025
- | Enrollment change: An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy (clinicaltrials.gov) - May 19, 2026
P2, N=40, Recruiting, Sponsor: Fudan University
Initiation date: Aug 2025 --> Nov 2025 N=20 --> 40
- || AiTan (rivoceranib) / Elevar Therapeutics, AiRuiKa (camrelizumab) / Elevar Therapeutics
P2 data, Journal, PD(L)-1 Biomarker, IO biomarker: Efficacy and Safety of Camrelizumab Plus Apatinib in Patients With Refractory Chordoma: A Phase II Clinical Trial. (Pubmed Central) - May 17, 2026
P2
Combination of camrelizumab and apatinib offered encouraging efficacy with manageable toxicity in chordoma treatment. CDKN2A alterations are associated with worse prognosis and may prove to be a potential biomarker for treatment selection.
- || tizetatug rezetecan (SHR-A1921) / Jiangsu Hengrui Pharma
P2 data, Journal: A Phase II study of SHR-A1921, a TROP2-targeted antibody-drug conjugate, in patients with recurrent or metastatic salivary gland carcinoma. (Pubmed Central) - May 17, 2026
P2
Trial registration: ClinicalTrials.gov, NCT05924256. Registered on June 29, 2023.
- | Tevimbra (tislelizumab-jsgr) / BeOne Medicines, Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, AiRuiKa (camrelizumab) / Elevar Therapeutics
Enrollment open, Trial completion date, Trial primary completion date, Real-world evidence: Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC) (clinicaltrials.gov) - May 15, 2026
P=N/A, N=2000, Recruiting, Sponsor: Qun Zhao
Registered on June 29, 2023. Not yet recruiting --> Recruiting | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Dec 2027
- | Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma
New P4 trial: Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP (clinicaltrials.gov) - May 15, 2026
P4, N=59, Not yet recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
- | AiTan (rivoceranib) / Elevar Therapeutics, AiRuiKa (camrelizumab) / Elevar Therapeutics
New P1/2 trial: HAIC-TACE Plus Apatinib and Camrelizumab for Liver Cancer (clinicaltrials.gov) - May 14, 2026
P1/2, N=315, Not yet recruiting, Sponsor: Shanghai Zhongshan Hospital
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: NAT-ESCC-01: Adebrelimab Plus Full-course Neoadjuvant Therapy for Resectable Locally Advanced ESCC (Phase 2) (clinicaltrials.gov) - May 14, 2026
P2, N=200, Not yet recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- | Hetronifly (serplulimab) / Alvogen, Shanghai Henlius Biotech
Enrollment open, Trial initiation date: A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer (clinicaltrials.gov) - May 14, 2026
P3, N=444, Recruiting, Sponsor: Tao Zhang
Not yet recruiting --> Recruiting | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Dec 2027 Initiation date: Feb 2026 --> May 2026 | Not yet recruiting --> Recruiting
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial, IO biomarker: Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer (clinicaltrials.gov) - May 13, 2026
P2, N=43, Not yet recruiting, Sponsor: Jiangmen Central Hospital
- | Enrollment open, Trial completion date, Trial primary completion date, Checkpoint inhibition: Clinical Study on the Prevention of Driver Gene Negative Ib-IIIb Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors (clinicaltrials.gov) - May 13, 2026
P=N/A, N=367, Recruiting, Sponsor: Shanghai University of Traditional Chinese Medicine
Initiation date: Feb 2026 --> May 2026 | Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
- AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis, Rinvoq (upadacitinib) / AbbVie
JAK inhibitors as salvage therapy in refractory hidradenitis suppurativa: a real-world case series () - May 13, 2026 - Abstract #EADVSp2026EADV_Sp_188;
Responses were heterogeneous, and higher dosing may be required for deep or fibrotic disease components, while interruption may lead to quick relapse. Larger controlled studies are needed to define optimal dosing strategies, durability, and the patient subgroups most likely to benefit.
- | Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma
New P1 trial: Neoadjuvant SHR-A1811 and SHR-A1701 for Potentially Immunotherapy-Sensitive GC or GEJ Adenocarcinoma (clinicaltrials.gov) - May 13, 2026
P1, N=12, Not yet recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
- ||||| HRS-5965 / Jiangsu Hengrui Pharma
New P2 trial: A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy (clinicaltrials.gov) - May 12, 2026
P2, N=380, Not yet recruiting, Sponsor: Chengdu Suncadia Medicine Co., Ltd.
- | Herceptin (trastuzumab) / Roche, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, Perjeta (pertuzumab) / Roche
New P2 trial: SPECTACLE: Study of Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast Cancer (clinicaltrials.gov) - May 12, 2026
P2, N=140, Not yet recruiting, Sponsor: Fudan University
- Nailike (olverembatinib) / Takeda
OLVEREMBATINIB AND HIGH-DOSE METHOTREXATE IN ACUTE LYMPHOBLASTIC LEUKEMIA: DELAYED METHOTREXATE CLEARANCE AND INCREASED NEPHROTOXICITY () - May 12, 2026 - Abstract #EHA2026EHA_4803;
This study presents a preliminary investigation into the drug-drug interaction between HD-MTX and TKIs, providing valuable insights for treatment optimization. In light of the elevated risk of nephrotoxicity identified, temporarily withholding olverembatinib during the peri-infusion period of HD-MTX is recommended to avoid potentially severe adverse effects.
- Venclexta (venetoclax) / Roche, AbbVie, Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma
EFFICACY AND SAFETY OF THE FLUMATINIB, VENETOCLAX, VINCRISTINE, AND PREDNISONE (FVVP) REGIMEN IN NEWLY DIAGNOSED ADULT PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA () - May 12, 2026 - Abstract #EHA2026EHA_4753;
In light of the elevated risk of nephrotoxicity identified, temporarily withholding olverembatinib during the peri-infusion period of HD-MTX is recommended to avoid potentially severe adverse effects. The FVVP regimen represents an effective, safe and cost-effective therapeutic option for Ph+ ALL, warranting further multicenter prospective validation to optimize long-term efficacy.
- Calquence (acalabrutinib) / AstraZeneca, Imbruvica (ibrutinib) / AbbVie, J&J
REAL-WORLD OUTCOMES IN PATIENTS WITH CLL TREATED WITH FIRST-LINE IBRUTINIB OR ACALABRUTINIB AND UNDERGOING DOSE REDUCTIONS: A CHART REVIEW STUDY () - May 12, 2026 - Abstract #EHA2026EHA_4737;
This abstract is embargoed until Thursday, June 11, 2026, 08:00 CEST.Presentation during EHA2026:All (e)Poster presentations will be made available as of until Thursday, June 11, 2026, 08:00 CEST and will be accessible for on-demand viewing from June 17 to October 15, 2026 on the Congress platform. Flumatinib-based combination chemotherapy represents an effective and safe therapeutic option for Ph+ ALL, further multicenter prospective validation for long-term efficacy optimization.
- Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma
ERIC REAL-WORLD RETROSPECTIVE ANALYSIS OF OUTCOMES IN CLL PATIENTS TREATED WITH CHEMOTHERAPY-FREE FRONTLINE TARGETED THERAPIES DEMONSTRATES THE IMPACT OF TP53 DISRUPTION IN THE ERA OF NOVEL THERAPY. () - May 12, 2026 - Abstract #EHA2026EHA_4704;
This study validates our prognostic system in elderly pts with BCR::ABL1+ ALL, revealing a previously unrecognized subgroup (non-IKZF1plus/MRD-) with a favorable prognosis. Furthermore, for high-risk pts in this poor-outcome population, CAR-T therapy may offer a viable treatment strategy.
- HRS-5965 / Jiangsu Hengrui Pharma, Fabhalta (iptacopan) / Novartis
EFFICACY ANALYSIS OF SWITCHING FROM C5 TO FACTOR B INHIBITORS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A REAL-WORLD STUDY () - May 12, 2026 - Abstract #EHA2026EHA_4493;
Factor B inhibitors show promising potential in individualized treatment strategies for PNH. Larger sample sizes and longer-term follow-up are required to further validate their efficacy and safety.
- Promacta (eltrombopag) / Novartis, Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
A MULTICENTER CLINICAL STUDY COMPARING HETROMBOPAG AND ELTROMBOPAG FOR PLATELET ENGRAFTMENT AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION () - May 12, 2026 - Abstract #EHA2026EHA_4480;
Larger sample sizes and longer-term follow-up are required to further validate their efficacy and safety. Collectively, our work has the potential to uncover novel epitranscriptome-based programs shaping translation and hematopoietic cell-fate commitment, with broad clinical implications for treating aggressive hematological disorders characterized by aberrant protein synthesis and MYC dysregulation.
- Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
FIRST-LINE HETROMBOPAG COMBINED WITH IMMUNOSUPPRESSIVE THERAPY FOR PEDIATRIC SEVERE APLASTIC ANEMIA: A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL () - May 12, 2026 - Abstract #EHA2026EHA_4183;
We provide the age of over 55 years as a single factor for clinical decision-making regarding the need for storage of excess cells. This could reduce the financial and technical burden of an excessive long-time transplant storage.
- HRS-5965 / Jiangsu Hengrui Pharma
EFFICACY AND SAFETY OF HRS-5965 IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS WITH PERSISTENT ANEMIA DESPITE STABLE C5 INHIBITOR THERAPY: A MULTICENTER, SINGLE-ARM, OPEN-LABEL PHASE 3 STUDY () - May 12, 2026 - Abstract #EHA2026EHA_4141;
In-hospital mortality for MM in Spain has significantly improved between 2020 and 2023. However, the presence of acute infectious complications and severe cardiovascular or cerebrovascular comorbidities remains a critical determinant of survival, outweighing the impact of age alone.
- HRS-5965 / Jiangsu Hengrui Pharma, Soliris (eculizumab) / AstraZeneca
EFFICACY AND SAFETY OF HRS-5965 VERSUS ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED PHASE 3 TRIAL () - May 12, 2026 - Abstract #EHA2026EHA_4139;
The high frequency of refractoriness, particularly in later lines, demonstrates substantial unmet need and the limited durability of available therapeutic options in LEN-E and LEN-R patients. These findings underscore the importance of novel therapeutic mechanisms and optimized treatment sequencing for patients with RRMM who progress after LEN exposure.
- Nplate (romiplostim) / Amgen, Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
YUPINGFENG FOR THE MANAGEMENT OF PERSISTENT THROMBOCYTOPENIA FOLLOWING IMMUNOTHERAPIES: A CASE SERIES () - May 12, 2026 - Abstract #EHA2026EHA_4094;
This series provides the first clinical evidence that Yupingfeng may be a highly effective and well-tolerated therapeutic option for managing immunotherapy-associated thrombocytopenia, particularly in TPO-RA refractory cases, while its early application shows potential for preventing persistent cytopenia development. These compelling findings warrant formal prospective investigation.
- Promacta (eltrombopag) / Novartis, Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
EARLY MOLECULAR KINETICS PREDICT DEEP MOLECULAR RESPONSE AND INFORM FRONTLINE TKI SELECTION IN PEDIATRIC CHRONIC MYELOID LEUKEMIA: A REAL-WORLD MULTICENTER STUDY () - May 12, 2026 - Abstract #EHA2026EHA_3954;
P4
Background: Anti-thymocyte globulin(ATG)and cyclosporine combined with TPO-RA is the first-line recommendation for patients with severe aplastic anemia (SAA) who are not eligible for hematopoietic stem cell transplantation.The addition of TPO-RA to immunosuppressive therapy significantly improves the depth of hematological response and early response speed in SAA patients.Previous trials from NIH and EBMT limited TPO-RA to a maximum of 6 months...Patients received ATG and CsA without TPO-RA(AC cohort n=86),combined with extended TPO-RA(ACHE cohort n=176)including hetrombopag (ACH cohort n=98) or eltrombopag (ACE cohort n=78)... Extended TPO-RA stratedy provides a time-dependent, sustained deep remission without additional AE concerns including clonal evolution.OR obtains a plateau after 12 months, CR demonstrates progressive benefits over time, extending up to 24 months post-ATG.
- Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
PROGNOSTIC IMPACT OF ADDITIONAL SOMATIC MUTATIONS ON TKD DEVELOPMENT, MOLECULAR RESPONSE AND SURVIVAL IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS () - May 12, 2026 - Abstract #EHA2026EHA_3941;
The addition of Hetrombopag to standard IST did not significantly improve the 6-month CR rate or OR rate in children with newly diagnosed SAA. Routine upfront combination with Hetrombopag is not necessary for most pediatric SAA patients.